Cargando…
Higher aorta dose increased neutrophil‐to‐lymphocyte ratio resulting in poorer outcomes in stage II‐III non‐small cell lung cancer
BACKGROUND: This study focused on the relationship between the neutrophil‐to‐lymphocyte ratio (NLR) and the dose of organs at risk in patients with stage II–III non‐small cell lung cancer (NSCLC) receiving intensity‐modulated radiotherapy. METHODS: The clinical characteristics and dosimetric paramet...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968602/ https://www.ncbi.nlm.nih.gov/pubmed/36604971 http://dx.doi.org/10.1111/1759-7714.14778 |
_version_ | 1784897533717250048 |
---|---|
author | Li, Yaqi Fan, Xingwen Yu, Qi Zhai, Haoyang Mi, Jing Lu, Renquan Jiang, Guoliang Wu, Kailiang |
author_facet | Li, Yaqi Fan, Xingwen Yu, Qi Zhai, Haoyang Mi, Jing Lu, Renquan Jiang, Guoliang Wu, Kailiang |
author_sort | Li, Yaqi |
collection | PubMed |
description | BACKGROUND: This study focused on the relationship between the neutrophil‐to‐lymphocyte ratio (NLR) and the dose of organs at risk in patients with stage II–III non‐small cell lung cancer (NSCLC) receiving intensity‐modulated radiotherapy. METHODS: The clinical characteristics and dosimetric parameters of 372 patients were collected retrospectively. A high NLR was defined as that ≥1.525. Survival analysis was conducted using the Kaplan–Meier and Cox regression analysis. Least absolute shrinkage and selection operator (LASSO) analysis was conducted to select appropriate dosimetric parameters. The risk factors of NLR were evaluated using univariate and multivariate logistic regression analyses. RESULTS: Patients with a high NLR had poorer progression‐free survival (PFS) (p = 0.011) and overall survival (OS) (p = 0.061). A low NLR (<1.525) predicted better PFS (hazard ratio [HR] 0.676, 95% confidence interval [CI]: 0.508–0.900, p = 0.007) and OS (HR 0.664, 95% CI: 0.490–0.901, p = 0.009). The aorta dose differed between the low and high NLR groups (all <0.1) in the univariate analysis. An aorta V10 was confirmed as a significant risk factor for a high NLR (odds ratio [OR] 1.029, 95% CI: 1.011–1.048, p = 0.002). Receiving chemotherapy before (OR 0.428, 95% CI: 0.225–0.813, p = 0.010) and during (OR 0.491, 95% CI: 0.296–0.815, p = 0.006) radiotherapy were predictive factors of a low NLR. CONCLUSION: The aorta dose was significantly associated with a high NLR. Patients with stage II–III NSCLC with a high NLR had poorer prognosis. Receiving chemotherapy before and/or during radiotherapy predicted a low NLR. |
format | Online Article Text |
id | pubmed-9968602 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-99686022023-02-28 Higher aorta dose increased neutrophil‐to‐lymphocyte ratio resulting in poorer outcomes in stage II‐III non‐small cell lung cancer Li, Yaqi Fan, Xingwen Yu, Qi Zhai, Haoyang Mi, Jing Lu, Renquan Jiang, Guoliang Wu, Kailiang Thorac Cancer Original Articles BACKGROUND: This study focused on the relationship between the neutrophil‐to‐lymphocyte ratio (NLR) and the dose of organs at risk in patients with stage II–III non‐small cell lung cancer (NSCLC) receiving intensity‐modulated radiotherapy. METHODS: The clinical characteristics and dosimetric parameters of 372 patients were collected retrospectively. A high NLR was defined as that ≥1.525. Survival analysis was conducted using the Kaplan–Meier and Cox regression analysis. Least absolute shrinkage and selection operator (LASSO) analysis was conducted to select appropriate dosimetric parameters. The risk factors of NLR were evaluated using univariate and multivariate logistic regression analyses. RESULTS: Patients with a high NLR had poorer progression‐free survival (PFS) (p = 0.011) and overall survival (OS) (p = 0.061). A low NLR (<1.525) predicted better PFS (hazard ratio [HR] 0.676, 95% confidence interval [CI]: 0.508–0.900, p = 0.007) and OS (HR 0.664, 95% CI: 0.490–0.901, p = 0.009). The aorta dose differed between the low and high NLR groups (all <0.1) in the univariate analysis. An aorta V10 was confirmed as a significant risk factor for a high NLR (odds ratio [OR] 1.029, 95% CI: 1.011–1.048, p = 0.002). Receiving chemotherapy before (OR 0.428, 95% CI: 0.225–0.813, p = 0.010) and during (OR 0.491, 95% CI: 0.296–0.815, p = 0.006) radiotherapy were predictive factors of a low NLR. CONCLUSION: The aorta dose was significantly associated with a high NLR. Patients with stage II–III NSCLC with a high NLR had poorer prognosis. Receiving chemotherapy before and/or during radiotherapy predicted a low NLR. John Wiley & Sons Australia, Ltd 2023-01-05 /pmc/articles/PMC9968602/ /pubmed/36604971 http://dx.doi.org/10.1111/1759-7714.14778 Text en © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Li, Yaqi Fan, Xingwen Yu, Qi Zhai, Haoyang Mi, Jing Lu, Renquan Jiang, Guoliang Wu, Kailiang Higher aorta dose increased neutrophil‐to‐lymphocyte ratio resulting in poorer outcomes in stage II‐III non‐small cell lung cancer |
title | Higher aorta dose increased neutrophil‐to‐lymphocyte ratio resulting in poorer outcomes in stage II‐III non‐small cell lung cancer |
title_full | Higher aorta dose increased neutrophil‐to‐lymphocyte ratio resulting in poorer outcomes in stage II‐III non‐small cell lung cancer |
title_fullStr | Higher aorta dose increased neutrophil‐to‐lymphocyte ratio resulting in poorer outcomes in stage II‐III non‐small cell lung cancer |
title_full_unstemmed | Higher aorta dose increased neutrophil‐to‐lymphocyte ratio resulting in poorer outcomes in stage II‐III non‐small cell lung cancer |
title_short | Higher aorta dose increased neutrophil‐to‐lymphocyte ratio resulting in poorer outcomes in stage II‐III non‐small cell lung cancer |
title_sort | higher aorta dose increased neutrophil‐to‐lymphocyte ratio resulting in poorer outcomes in stage ii‐iii non‐small cell lung cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968602/ https://www.ncbi.nlm.nih.gov/pubmed/36604971 http://dx.doi.org/10.1111/1759-7714.14778 |
work_keys_str_mv | AT liyaqi higheraortadoseincreasedneutrophiltolymphocyteratioresultinginpooreroutcomesinstageiiiiinonsmallcelllungcancer AT fanxingwen higheraortadoseincreasedneutrophiltolymphocyteratioresultinginpooreroutcomesinstageiiiiinonsmallcelllungcancer AT yuqi higheraortadoseincreasedneutrophiltolymphocyteratioresultinginpooreroutcomesinstageiiiiinonsmallcelllungcancer AT zhaihaoyang higheraortadoseincreasedneutrophiltolymphocyteratioresultinginpooreroutcomesinstageiiiiinonsmallcelllungcancer AT mijing higheraortadoseincreasedneutrophiltolymphocyteratioresultinginpooreroutcomesinstageiiiiinonsmallcelllungcancer AT lurenquan higheraortadoseincreasedneutrophiltolymphocyteratioresultinginpooreroutcomesinstageiiiiinonsmallcelllungcancer AT jiangguoliang higheraortadoseincreasedneutrophiltolymphocyteratioresultinginpooreroutcomesinstageiiiiinonsmallcelllungcancer AT wukailiang higheraortadoseincreasedneutrophiltolymphocyteratioresultinginpooreroutcomesinstageiiiiinonsmallcelllungcancer |